Novavax, Inc. announced the initiation of its Phase IIb/III Hummingbird™ global clinical trial. The trial will evaluate the safety, effectiveness, and efficacy of two doses of the Novavax COVID-19 vaccine in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series.
[Novavax, Inc.]